Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q, Klein C, Caruso S, Maille P, Allende DS, Mínguez B, Iavarone M, Ningarhari M, Casadei-Gardini A, Pedica F, Rimini M, Perbellini R, Boulagnon-Rombi C, Heurgué A, Maggioni M, Rela M, Vij M, Baulande S, Legoix P, Lameiras S; HCC-AI study group; Bruges L, Gnemmi V, Nault JC, Campani C, Rhee H, Park YN, Iñarrairaegui M, Garcia-Porrero G, Argemi J, Sangro B, D'Alessio A, Scheiner B, Pinato DJ, Pinter M, Paradis V, Beaufrère A, Peter S, Rimassa L, Di Tommaso L, Vogel A, Michalak S, Boursier J, Loménie N, Ziol M, Calderaro J. Zeng Q, et al. Lancet Oncol. 2023 Dec;24(12):1411-1422. doi: 10.1016/S1470-2045(23)00468-0. Epub 2023 Nov 8. Lancet Oncol. 2023. PMID: 37951222
The atezolizumab-bevacizumab response signature (ABRS), assessed by molecular biology profiling techniques, has been shown to be associated with progression-free survival after treatment initiation. The primary objective of our study was to develop an artificial intelligen …
The atezolizumab-bevacizumab response signature (ABRS), assessed by molecular biology profiling techniques, has been shown to be associat …
Enhancing patient-centered care with AI: a study of responses to neuroendocrine neoplasms queries.
Panzuto F, Gallo A, Marini M, Rinzivillo M, Albertelli M, Grana CM, Maccauro M, Milione M, Tafuto S, Barbi S, Partelli S; Italian Association for Neuroendocrine Tumors AI study group; NET-Italy patient advocacy group. Panzuto F, et al. Endocrine. 2025 Jun 5. doi: 10.1007/s12020-025-04294-9. Online ahead of print. Endocrine. 2025. PMID: 40471488
INTRODUCTION: Large Language Models (LLMs) are increasingly used in oncology, but their application in neuroendocrine neoplasms (NENs) is still unexplored. AIM: To evaluate the accuracy, clarity, and completeness of LLM responses to clinically relevant NEN management quest …
INTRODUCTION: Large Language Models (LLMs) are increasingly used in oncology, but their application in neuroendocrine neoplasms (NENs …